UBS AM
WVE icon

UBS AM’s Wave Life Sciences WVE Stock Holding History

UBS AM’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Sell
2,900
-222,214
-99% -$1.47M ﹤0.01% 3156
2026
Q1 		$1.63M Buy
225,114
+60,129
+36% +$783K ﹤0.01% 2133
2025
Q4 		$2.8M Buy
+164,985
New +$1.68M ﹤0.01% 1738
2025
Q3 		– Sell
-295,061
Closed -$1.92M – 2635
2025
Q2 		$1.92M Buy
295,061
+111,659
+61% +$737K ﹤0.01% 2160
2025
Q1 		$1.48M Buy
183,402
+18,164
+11% +$199K ﹤0.01% 2139
2024
Q4 		$2.04M Buy
165,238
+20,520
+14% +$274K ﹤0.01% 2034
2024
Q3 		$1.19M Sell
144,718
-26,331
-15% -$157K ﹤0.01% 2311
2024
Q2 		$854K Buy
171,049
+95,996
+128% +$548K ﹤0.01% 2454
2024
Q1 		$463K Buy
75,053
+18,027
+32% +$90.3K ﹤0.01% 2309
2023
Q4 		$288K Buy
+57,026
New +$305K ﹤0.01% 2425
2021
Q2 		– Sell
-22,605
Closed -$127K – 2783
2021
Q1 		$127K Sell
22,605
-12,146
-35% -$117K ﹤0.01% 2585
2020
Q4 		$273K Buy
34,751
+8,863
+34% +$74.4K ﹤0.01% 2431
2020
Q3 		$220K Buy
25,888
+2,596
+11% +$28.5K ﹤0.01% 2383
2020
Q2 		$242K Buy
+23,292
New +$219K ﹤0.01% 2340
2019
Q3 		– Sell
-8,507
Closed -$222K – 2905
2019
Q2 		$222K Sell
8,507
-134,301
-94% -$3.77M ﹤0.01% 2510
2019
Q1 		$5.55M Buy
142,808
+4,707
+3% +$191K ﹤0.01% 1112
2018
Q4 		$5.81M Sell
138,101
-12,318
-8% -$548K 0.01% 1042
2018
Q3 		$7.52M Buy
150,419
+5,477
+4% +$247K 0.01% 1009
2018
Q2 		$5.54M Buy
+144,942
New +$6.24M ﹤0.01% 1116

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

UBS AM's WVE Position: Q2 2026 in Review

UBS AM reduced its Wave Life Sciences (WVE) stake by 99% in Q2 2026, selling an estimated $1.47M and leaving 2,900 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3156.

UBS AM first reported a position in WVE in Q2 2018 and has held it in 19 quarters since. The position peaked at $7.52M in Q3 2018. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • UBS AM held 2,900 shares of Wave Life Sciences worth $16.8K as of Q2 2026.
  • UBS AM sold 222,214 Wave Life Sciences shares in Q2 2026, an estimated $1.47M.
  • Wave Life Sciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3156 holding.
  • UBS AM first reported a position in Wave Life Sciences in Q2 2018 and has held it in 19 quarters since.
  • UBS AM's Wave Life Sciences position peaked at $7.52M in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.